COVID-19 Comorbidity

Researchers in Lille, France studied patients admitted to intensive care for COVID-19 and concluded that Obesity is a risk factor for severity. It has been recommended that quarantine of obese subjects be extended longer than nonobese patients.[1]

Black Americans are being disproportionately affected by COVID-19.[2]  The increased incidence of obesity among the Black population who are concentrated in our inner cities is most likely responsible.

Diabetes mellitus modulates host immune response and host-virus interaction to increase morbidity. [3] As it is the visceral or “belly fat” within the abdomen which secretes resistin, a cellular hormone which antagonizes the body’s own insulin to cause type 2 diabetes, reducing the size of that noxious cytokine factory which functions as a life-shortening gland with Endoscopic Visceral Lipectomy is potentially a direct approach to the problem if carried out sufficiently ahead of time.

A societal effort must be made to reduce the vulnerability of these obese and diabetic sectors of the population to COVID-19 and future pandemics. Obesity, metabolic syndrome and type 2 diabetes need not just to be maintained under control, but efforts should be made to prevent, eliminate and cure them. 

Governments need to make existing modalities and treatments available to everyone, especially those in inner cities, or these hosts will remain as soft targets and as breeding pools for the next pandemic. They will comprise the majority of admissions and fatalities. Fortify the herd or nature will cull it at our expense.

[1]  High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M; Lille Intensive Care COVID-19 and Obesity study group. Obesity (Silver Spring). 2020 Apr 9. doi: 10.1002/oby.22831. [Epub ahead of print]


[3] COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Muniyappa R, Gubbi S. Am J Physiol Endocrinol Metab. 2020 Mar 31. doi: 10.1152/ajpendo.00124.2020. [Epub ahead of print] PMID: 32228322